Guangzhou Dabuo Biopharmaceutical

Guangzhou Dabo Biopharmaceutical is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on oncology, with a pipeline centered on highly selective kinase inhibitors. Its lead candidate, DB-101, is a potent FGFR inhibitor currently being evaluated in clinical trials for various solid tumors, including cholangiocarcinoma and urothelial carcinoma. Dabo Biopharmaceutical leverages its proprietary drug discovery platform to target unmet medical needs in cancer and other complex diseases. The company was founded by experienced industry veterans and has received backing from regional venture capital firms in the Guangdong area.